Department of Internal Medicine, Colentina Hospital, Bucharest, Romania.
University of Medicine and Pharmacy Carol Davila Bucharest, Bucharest, Romania.
J Eval Clin Pract. 2020 Dec;26(6):1579-1582. doi: 10.1111/jep.13484. Epub 2020 Sep 21.
There was no evidence concerning the prophylaxis with hydroxychloroquine, and only low-grade evidence regarding the use of hydroxychloroquine as a treatment for COVID-19 patients. We performed a survey among Romanian physicians in order to see how many of them would administer prophylactically hydroxychloroquine to themselves or to people close to them, and if they would participate to a randomized controlled trial.
Between March 30 and April 02, 2020, a 16-item questionnaire was shared in a Romanian Facebook group of 2645 physicians dedicated to COVID-19 information, asking to be completed by physicians who could be directly involved in the care of these patients.
A total of 785 answers were collected. Nine physicians (1.1%) thought that there was clear evidence on prescribing hydroxychloroquine prophylaxis, 375 (48%) considered the evidence acceptable, 348 (44.3%) considered it weak, whereas 53 (6.8%) answered there was no evidence. 59 (7.5%) respondents were determined to take it (of which 31 = 4% already took), 192 (24.5%) were inclined to take, 271 (34.5%) were not decided yet. 175 (22.3%) of respondents declared they (would) give the treatment to their close ones, and this decision was associated with a higher age (P = 0.003), and the opinion that there was evidence (P < 0.001). When asked about the source of the treatment regimen, 286 (36.4%) indicated a scientific paper, while no scientific paper about the prophylaxis with hydroxychloroquine existed at that time. 718 (91.5%) considered a randomized clinical trial necessary (RCT), but only 333 (42.4%) answered they would enrol in such a trial. There was only a very weak correlation (Kendall's tau _b = 0.255, P < 0.001) between the belief that an RCT is necessary and the willingness to enrol in such an RCT.
Despite the lack of evidence, many physicians considered the evidence as existing, and were ready to take or to give hydroxychloroquine prophylactically to family. They considered an RCT necessary, but they were not willing to participate.
没有关于羟氯喹预防作用的证据，只有低质量证据表明羟氯喹可用于治疗 COVID-19 患者。我们对罗马尼亚医生进行了一项调查，以了解他们中有多少人会预防性地给自己或身边的人使用羟氯喹，以及他们是否愿意参加随机对照试验。
2020 年 3 月 30 日至 4 月 2 日，我们在一个有 2645 名医生的罗马尼亚 Facebook 群组中分享了一份包含 16 个问题的问卷，询问那些可能直接参与这些患者护理的医生是否愿意完成问卷。
共收集到 785 份答卷。9 名医生（1.1%）认为有明确证据表明羟氯喹预防作用有效，375 名（48%）认为证据可接受，348 名（44.3%）认为证据较弱，53 名（6.8%）认为没有证据。59 名（7.5%）受访者表示他们将服用该药（其中 31 名=4%已服用），192 名（24.5%）倾向于服用，271 名（34.5%）尚未决定。175 名（22.3%）受访者表示他们（将）将该治疗方法用于自己的亲人，这一决定与年龄较大（P=0.003）和认为有证据（P<0.001）相关。当被问及治疗方案的来源时，286 名（36.4%）受访者表示是科学论文，而当时并没有关于羟氯喹预防作用的科学论文。718 名（91.5%）受访者认为有必要进行随机临床试验（RCT），但只有 333 名（42.4%）表示他们将参加此类试验。尽管认为 RCT 是必要的，但他们并不愿意参加。他们之间只有很弱的相关性（肯德尔 tau _b=0.255，P<0.001）。
尽管缺乏证据，但许多医生认为有证据存在，并准备预防性地使用羟氯喹或给予家人羟氯喹。他们认为 RCT 是必要的，但他们不愿意参与。
